UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2020, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2020. A copy of the Press Release is furnished herewith as Exhibit 99.1.
On October 28, 2020, Nektar announced that it would hold a Webcast conference call on November 5, 2020 to review its financial results for the quarter ended September 30, 2020. This conference call is accessible through a link that is posted on the home page and Investors section of the Nektar website: http://ir.nektar.com.
The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press release titled “Nektar Therapeutics Reports Third Quarter 2020 Financial Results” issued by Nektar Therapeutics on November 5, 2020. | |
1
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| By: | /s/ Mark A. Wilson | |
| Mark A. Wilson | ||
| General Counsel and Secretary | ||
| Date: | November 5, 2020 |
2
Exhibit 99.1
Nektar Therapeutics Reports Third Quarter 2020 Financial Results
SAN FRANCISCO, November 5, 2020 -- Nektar Therapeutics (NASDAQ: NKTR) today reported financial results for the third quarter ended September 30, 2020.
Cash and investments in marketable securities at September 30, 2020 were approximately $1.2 billion as compared to $1.6 billion at December 31, 2019.
"In Q3, we’ve continued to successfully advance our late-stage registrational and early stage studies for our immune-oncology pipeline of candidates while navigating challenges in the current COVID-19 environment,” said Howard W. Robin, President and CEO of Nektar. “Enrollment in our five registrational trials of bempegaldesleukin in combination with nivolumab is going well and our partner BMS recently initiated a new clinical study in renal cell carcinoma to evaluate the doublet therapy with a TKI agent. We are also pleased to report that we are ahead of our enrollment targets for the Phase 2 PROPEL study of bempegaldesleukin with pembrolizumab in patients with metastatic non-small cell lung cancer and we look forward to sharing the initial data from this important study in the first part of 2021.”
“Next week’s 2020 SITC meeting will feature data presentations that showcase the strength of Nektar’s immune-oncology pipeline, including an oral presentation of 2 1/2 year data for metastatic melanoma patients treated with bempegaldesleukin plus nivolumab, and promising early data for NKTR-255, our IL-15 cytokine, as well as NKTR-262, our TLR agonist program,” continued Robin. “In immunology, we presented positive new data at ACR 2020 this week highlighting the disease activity observed in lupus patients with NKTR-358, our T regulatory cell agent. We are exceptionally pleased that our partner Lilly is undertaking a broad clinical development program for NKTR-358 with two Phase 1b studies in atopic dermatitis and psoriasis, a Phase 2 study underway in patients with systemic lupus erythematosus and a new Phase 2 study being planned in ulcerative colitis.”
Summary of Q3 2020 Financial Results
Revenue in the third quarter of 2020 was $30.0 million compared to $29.2 million in the third quarter of 2019. Year-to-date revenue for 2020 was $129.5 million compared to $80.8 million for the first nine months of 2019. Revenue was higher due to the recognition of $50.0 million in total milestones from Bristol-Myers Squibb related to the start of two new registrational trials of bempegaldesleukin plus Opdivo® in adjuvant melanoma and muscle-invasive bladder cancer.
Total operating costs and expenses in the third quarter of 2020 were $133.1 million compared to $128.0 million in the third quarter of 2019. Total operating costs and expenses in the first nine months of 2020 were $443.8 million compared to $411.2 million in the first nine months of 2019. Year-to-date operating costs and expenses increased primarily as a result of $45.2 million in impairment charges in the first quarter of 2020 resulting from the discontinuation of the NKTR-181 program, partially offset by a decrease in R&D expense.
R&D expense in the third quarter of 2020 was $100.5 million compared to $99.0 million for the third quarter of 2019. For the first nine months of 2020, R&D expense was $306.0 million compared to $324.2 million in the first nine months of 2019. Excluding pre-commercial manufacturing costs for NKTR-181 incurred during 2019, research and development expense increased for the third quarter and the first nine months of 2020 primarily due to increases in clinical development costs, partially offset by a decrease in manufacturing costs for clinical trial materials.
Net loss for the third quarter of 2020 was $108.6 million or $0.61 basic and diluted loss per share compared to a net loss of $98.6 million or $0.56 basic and diluted loss per share in the third quarter of 2019. Net loss in the first nine months of 2020 was $327.2 million or $1.84 basic and diluted loss per share compared to a net loss of $328.5 million or $1.88 basic and diluted loss per share in the first nine months of 2019.
1
Third Quarter 2020 and Recent Business Highlights
| ● | In November 2020, Nektar presented new data from its NKTR-358 program at the American College of Rheumatology (ACR) virtual meeting. Data from the Phase 1b study in patients with mild to moderate systemic lupus erythematosus (SLE) showed that NKTR-358 produced a dose-dependent increase in expression of Treg activation markers, providing a rationale for continued development in SLE and other inflammatory indications. |
| ● | In October 2020, Nektar received IND clearance and began site initiation activities for a Phase 1/2 study of NKTR-255 in patients with solid tumors. The study will evaluate NKTR-255 in combination with cetuximab in two distinct groups of highly refractory patients with colorectal cancer or head and neck cancer. |
| ● | In October 2020, Nektar initiated a Phase 1b clinical study of bempegaldesleukin in adult patients with mild COVID-19 infection. The randomized, double-blind, placebo-controlled trial is designed to assess the safety, tolerability, and pharmacokinetic and pharmacodynamic profile of bempegaldesleukin in adult patients with mild COVD-19. |
| ● | In September 2020, a Phase 1/2 study was initiated by Nektar partner BMS in patients with clear cell renal cell carcinoma to evaluate the triplet combination of bempegaldesleukin with nivolumab in combination with a tyrosine-kinase inhibitor. |
| ● | In August 2020, Vaccibody AS and Nektar announced that the first patient had been dosed in the Phase 1/2a study evaluating bempegaldesleukin with VB10.NEO, Vaccibody's personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck. |
The company also announced upcoming presentations at the following scientific congress:
2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting:
| ● | Oral Presentation: “REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors” |
| o | Presenter: Dr. Adi Diab, MD Anderson Cancer Center |
| o | Session: Session 102: Combinatorial Therapies |
| o | Date and Time: Wednesday, November 11; 11:15 a.m. – 1:10 p.m. Eastern Standard Time |
| ● | Oral Presentation: “Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study” |
| o | Presenter: Dr. Adi Diab, MD Anderson Cancer Center |
| o | Session: Session 104: Concurrent Rapid Oral Abstract Presentation: Clinical |
| o | Date and Time: Wednesday, November 11; 1:30 p.m. – 2:00 p.m. Eastern Standard Time |
| ● | Poster Presentation: “First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies”, Shah, N., et al. |
| o | Session: Virtual Poster Hall |
| o | Date and Time: Poster presentations will be available beginning November 9, 2020 |
| ● | Poster Presentation: “Bempegaldesleukin (BEMPEG; CD122-preferential IL-2 pathway agonist)) and NKTR-262 (TLR7/8 agonist) combination treatment pairs local innate immune activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity”, Rolig, A., et al. |
| o | Session: Virtual Poster Hall |
| o | Date and Time: Poster presentations will be available beginning November 9, 2020 |
2
Conference Call to Discuss Third Quarter Financial Results
Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, today, Thursday, November 5, 2020.
This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through Tuesday, December 1, 2020.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Conference ID: 5192707 (Nektar Therapeutics is the host)
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Cautionary Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements which can be identified by words such as: "may," "design,"
"potential," "evaluate," "plan," "will," and similar references to future periods. Examples
of forward-looking statements include, among others, statements we make regarding the therapeutic potential of, and future development
plans for, our clinical drug candidates, and the timing of the initiation of clinical studies for clinical drug candidates. Forward-looking
statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,
expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends,
the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.
Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely
on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those
indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of bempegaldesleukin
in patients who have been diagnosed with COVID-19 infection are based on data that is evolving and do not include clinical testing
of bempegaldesleukin for this intended patient population, and there is no guarantee that the clinical evaluation of bempegaldesleukin
in COVID-19 patients will support the use of bempegaldesleukin in this patient population; (ii) our clinical drug candidates are
investigational agents and continued research and development for these drug candidates are subject to substantial risks, including
negative safety and efficacy findings in ongoing clinical studies (notwithstanding positive findings in earlier preclinical and
clinical studies); (iii) as our clinical drug candidates are currently in development, the risk of failure is high and failure
can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement or end of clinical trials
and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient
enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical
outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets;
(v) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable,
or additional intellectual property licenses from third parties may be required; and (vi) certain other important risks and uncertainties
set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2020. Any forward-looking
statement made by us in this press release is based only on information currently available to us and speaks only as of the date
on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information, future developments or otherwise.
Contact:
For Investors:
Jerry Isaacson of Nektar Therapeutics
628-895-0634
Vivian Wu of Nektar Therapeutics
628-895-0661
For
Media:
Dan Budwick of 1AB
973-271-6085
Opdivo is a registered trademark of Bristol-Myers Squibb Company.
3
NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
| September 30, 2020 | December 31, 2019(1) | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 55,843 | $ | 96,363 | ||||
| Short-term investments | 900,163 | 1,228,499 | ||||||
| Accounts receivable | 42,925 | 36,802 | ||||||
| Inventory | 12,892 | 12,665 | ||||||
| Advance payments to contract manufacturers | 10,483 | 31,834 | ||||||
| Other current assets | 21,550 | 15,387 | ||||||
| Total current assets | 1,043,856 | 1,421,550 | ||||||
| Long-term investments | 197,715 | 279,119 | ||||||
| Property, plant and equipment, net | 60,189 | 65,665 | ||||||
| Operating lease right-of-use assets | 128,985 | 134,177 | ||||||
| Goodwill | 76,501 | 76,501 | ||||||
| Other assets | 1,420 | 344 | ||||||
| Total assets | $ | 1,508,666 | $ | 1,977,356 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Senior secured notes, net and interest payable | $ | — | $ | 252,891 | ||||
| Accounts payable | 15,484 | 19,234 | ||||||
| Accrued compensation | 29,504 | 11,467 | ||||||
| Accrued clinical trial expenses | 48,886 | 32,626 | ||||||
| Accrued contract manufacturing expenses | 7,141 | 7,304 | ||||||
| Other accrued expenses | 9,630 | 12,338 | ||||||
| Operating lease liabilities, current portion | 15,348 | 12,516 | ||||||
| Deferred revenue, current portion | 507 | 5,517 | ||||||
| Total current liabilities | 126,500 | 353,893 | ||||||
| Operating lease liabilities, less current portion | 139,022 | 142,730 | ||||||
| Liability related to the sale of future royalties, net | 66,378 | 72,020 | ||||||
| Deferred revenue, less current portion | 2,494 | 2,554 | ||||||
| Other long-term liabilities | 3,291 | 768 | ||||||
| Total liabilities | 337,685 | 571,965 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 18 | 17 | ||||||
| Capital in excess of par value | 3,363,998 | 3,271,097 | ||||||
| Accumulated other comprehensive income (loss) | (1,080 | ) | (1,005 | ) | ||||
| Accumulated deficit | (2,191,955 | ) | (1,864,718 | ) | ||||
| Total stockholders’ equity | 1,170,981 | 1,405,391 | ||||||
| Total liabilities and stockholders’ equity | $ | 1,508,666 | $ | 1,977,356 | ||||
| (1) | The consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. |
4
NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share information)
(Unaudited)
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product sales | $ | 5,691 | $ | 5,558 | $ | 14,620 | $ | 14,302 | ||||||||
| Royalty revenue | 12,289 | 10,275 | 31,411 | 29,008 | ||||||||||||
| Non-cash royalty revenue related to sale of future royalties | 10,422 | 10,264 | 28,001 | 27,585 | ||||||||||||
| License, collaboration and other revenue | 1,631 | 3,121 | 55,421 | 9,860 | ||||||||||||
| Total revenue | 30,033 | 29,218 | 129,453 | 80,755 | ||||||||||||
| Operating costs and expenses: | ||||||||||||||||
| Cost of goods sold | 5,570 | 4,927 | 15,154 | 15,385 | ||||||||||||
| Research and development | 100,531 | 99,048 | 305,954 | 324,197 | ||||||||||||
| General and administrative | 26,982 | 23,983 | 77,546 | 71,570 | ||||||||||||
| Impairment of assets and other costs for terminated program | — | — | 45,189 | — | ||||||||||||
| Total operating costs and expenses | 133,083 | 127,958 | 443,843 | 411,152 | ||||||||||||
| Loss from operations | (103,050 | ) | (98,740 | ) | (314,390 | ) | (330,397 | ) | ||||||||
| Non-operating income (expense): | ||||||||||||||||
| Interest expense | — | (5,425 | ) | (6,851 | ) | (15,882 | ) | |||||||||
| Non-cash interest expense on liability related to sale of future royalties | (8,425 | ) | (5,813 | ) | (22,084 | ) | (17,853 | ) | ||||||||
| Interest income and other income (expense), net | 2,910 | 11,492 | 16,453 | 35,964 | ||||||||||||
| Total non-operating income (expense), net | (5,515 | ) | 254 | (12,482 | ) | 2,229 | ||||||||||
| Loss before provision for income taxes | (108,565 | ) | (98,486 | ) | (326,872 | ) | (328,168 | ) | ||||||||
| Provision for income taxes | 21 | 99 | 365 | 335 | ||||||||||||
| Net loss | $ | (108,586 | ) | $ | (98,585 | ) | $ | (327,237 | ) | $ | (328,503 | ) | ||||
| Basic and diluted net loss per share | $ | (0.61 | ) | $ | (0.56 | ) | $ | (1.84 | ) | $ | (1.88 | ) | ||||
| Weighted average shares outstanding used in computing basic and diluted net loss per share | 179,090 | 175,402 | 178,203 | 174,609 | ||||||||||||
5
NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
| Nine months ended September 30, | ||||||||
| 2020 | 2019 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (327,237 | ) | $ | (328,503 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Non-cash royalty revenue related to sale of future royalties | (28,001 | ) | (27,585 | ) | ||||
| Non-cash interest expense on liability related to sale of future royalties | 22,084 | 17,853 | ||||||
| Stock-based compensation | 72,274 | 74,787 | ||||||
| Depreciation and amortization | 10,937 | 9,582 | ||||||
| Impairment of advance payments to contract manufacturers and equipment for terminated program | 20,351 | — | ||||||
| Accretion of premiums (discounts), net and other non-cash transactions | 1,150 | (9,147 | ) | |||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (6,123 | ) | 2,008 | |||||
| Inventory | (227 | ) | (2,339 | ) | ||||
| Operating leases, net | 4,316 | 11,550 | ||||||
| Other assets | (5,588 | ) | 18,127 | |||||
| Accounts payable | (3,337 | ) | 16,109 | |||||
| Accrued compensation | 20,478 | 13,164 | ||||||
| Other accrued expenses | 9,340 | 10,401 | ||||||
| Deferred revenue | (5,070 | ) | (9,465 | ) | ||||
| Net cash used in operating activities | (214,653 | ) | (203,458 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of investments | (791,445 | ) | (1,028,883 | ) | ||||
| Maturities of investments | 1,158,722 | 1,122,902 | ||||||
| Sales of investments | 41,700 | — | ||||||
| Purchases of property, plant and equipment | (5,504 | ) | (22,614 | ) | ||||
| Net cash provided by investing activities | 403,473 | 71,405 | ||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from shares issued under equity compensation plans | 20,651 | 18,449 | ||||||
| Repayment of senior notes | (250,000 | ) | — | |||||
| Net cash provided by (used in) financing activities | (229,349 | ) | 18,449 | |||||
| Effect of foreign exchange rates on cash and cash equivalents | 9 | (77 | ) | |||||
| Net decrease in cash and cash equivalents | (40,520 | ) | (113,681 | ) | ||||
| Cash and cash equivalents at beginning of period | 96,363 | 194,905 | ||||||
| Cash and cash equivalents at end of period | $ | 55,843 | $ | 81,224 | ||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | 9,742 | $ | 14,299 | ||||
| Operating lease right-of-use asset recognized in exchange for lease liabilities | $ | 2,133 | $ | 56,025 | ||||
6